- Home
- CYCC vs HSDT Comparison
CYCC vs HSDT Comparison
Compare CYCC & HSDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCC
- HSDT
- Stock Information
- Founded
- CYCC 1992
- HSDT 2014
- Country
- CYCC United States
- HSDT United States
- Employees
- CYCC N/A
- HSDT N/A
- Industry
- CYCC Biotechnology: Pharmaceutical Preparations
- HSDT Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- CYCC Health Care
- HSDT Health Care
- Exchange
- CYCC Nasdaq
- HSDT Nasdaq
- Market Cap
- CYCC 1.8M
- HSDT 1.8M
- IPO Year
- CYCC N/A
- HSDT N/A
- Fundamental
- Price
- CYCC $0.37
- HSDT $0.46
- Analyst Decision
- CYCC Buy
- HSDT Buy
- Analyst Count
- CYCC 2
- HSDT 2
- Target Price
- CYCC $11.00
- HSDT $24.00
- AVG Volume (30 Days)
- CYCC 3.7M
- HSDT 116.7K
- Earning Date
- CYCC 11-12-2024
- HSDT 11-12-2024
- Dividend Yield
- CYCC N/A
- HSDT N/A
- EPS Growth
- CYCC N/A
- HSDT N/A
- EPS
- CYCC N/A
- HSDT N/A
- Revenue
- CYCC $74,000.00
- HSDT $502,000.00
- Revenue This Year
- CYCC N/A
- HSDT $16.41
- Revenue Next Year
- CYCC $16.28
- HSDT $31.97
- P/E Ratio
- CYCC N/A
- HSDT N/A
- Revenue Growth
- CYCC N/A
- HSDT N/A
- 52 Week Low
- CYCC $0.35
- HSDT $0.37
- 52 Week High
- CYCC $6.00
- HSDT $9.50
- Technical
- Relative Strength Index (RSI)
- CYCC 29.98
- HSDT 39.76
- Support Level
- CYCC $0.35
- HSDT $0.44
- Resistance Level
- CYCC $0.52
- HSDT $0.58
- Average True Range (ATR)
- CYCC 0.07
- HSDT 0.06
- MACD
- CYCC -0.01
- HSDT 0.00
- Stochastic Oscillator
- CYCC 3.94
- HSDT 4.17
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.
About HSDT Helius Medical Technologies Inc. (DE)
Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS), is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.